Munich, Germany, April 9, 2013 / B3C newswire / - Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, today announced it has appointed Merrilyn Datta, Ph.D., as Chief Marketing Officer. Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
“I am very excited to have Merrilyn join our leadership team. Merrilyn’s expertise will be key to leverage our leadership position in image and data analysis in Life Sciences into Tissue Diagnostics and Clinical Digital Pathology,“ said Definiens CEO Thomas Heydler. “Merrilyn’s great track record in understanding the marketplace and building businesses will be invaluable for driving Definiens’ Marketing and Commercialization activities.”
Prior to joining Definiens, Dr. Datta served as a senior marketing leader for Life Technologies, a global biotechnology company with customers in the fields of scientific research, genetic analysis and applied sciences, where she specialized in technology commercialization and strategy. Her professional background also includes positions as Chief Content Officer, Services Leader and Gene Regulation BU leader.
“Definiens will take tissue analysis into the 21st century by making the information on histological slides accessible to bioinformatics analysis,” said Dr. Datta. “I’m excited to be a part of the team which will not only provide valuable image understanding to accelerate drug discovery, but which also has a roadmap to fundamentally change clinical practice, advance personalized medicine and improve patient outcomes.”
Dr. Datta is based in southern California and will lead Definiens’ marketing activities from the company’s Carlsbad office.
Definiens is the leading provider of image analysis and data mining solutions for life sciences, tissue diagnostics and clinical digital pathology. Definiens software provides detailed cell-by-cell readouts from target structures on whole tissue slides, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives.
Definiens is headquartered in Munich, Germany and has a North American office in Carlsbad, California. Further information is available at www.definiens.com.
Dr Florian Leiss
Manager Marketing Communications
+49 (89) 2311-8024